Feasibility of Using the CGM GUARDIAN 2 Interstitial Fluid Glucose Measurement System in Intensive Care Medicine

What this Trial Is About

Glycemic imbalances frequently occur in patients with septic shock admitted to intensive care units. Researchers are evaluating the feasibility of using the CGM GUARDIAN 2 system to measure glucose levels in interstitial fluid in these critically ill patients. This device has been validated in insulin-dependent diabetic patients but not yet tested in intensive care settings. The study focuses on patients with arterial hypotension requiring noradrenaline and hyperglycemia needing insulin therapy. The study involves using the CGM GUARDIAN 2 device, which includes an electrode placed on the patient's abdomen or arm for up to six days. This electrode has a subcutaneous needle inserted only during placement. A sensor attached to the electrode reads glucose levels every minute, averaging the data every five minutes. The device is linked to an insulin pump that does not deliver therapy but serves as an information reader to monitor glucose trends. Participants will have their glucose levels closely monitored throughout the study, with the primary outcome being the glucose level measured on day six. The study includes routine blood glucose measurements every two hours using fingertip capillary samples to compare with the device readings. The research team will assess glucose control feasibility, device performance, and patient comfort during intensive care. The total study duration for each participant is at least six days, with ongoing monitoring of glucose levels and related parameters.

Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine